Praxsyn Corporation (PXYN) Stock Price & Analysis
Educational signal · not a buy or sell recommendation · How to read this
Beta 0.49: the stock has moved about 51% less than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 17, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerPraxsyn Corporation (PXYN) trades at $0.00001. Praxsyn Corporation provides medical practitioners with medications and services, formulating non-narcotic treatments for pain management, erectile dysfunction, and metabolic therapies. Sector: Healthcare.
Price as of · Last analyzed: Mar 17, 2026Analyst Coverage for PXYN: PXYN does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage.
No score published: we hold no usable price for this ticker, and a grade beside a missing price says nothing.
Praxsyn Corporation (PXYN) Healthcare & Pipeline Overview
Praxsyn Corporation develops and distributes non-narcotic medications for pain management, erectile dysfunction, and metabolic therapies, primarily serving patients within the California workers' compensation system. Operating in the competitive pharmaceutical sector, Praxsyn focuses on alternative treatments to traditional narcotics.
What Is the Investment Thesis for PXYN?
Praxsyn Corporation operates in a niche market, providing non-narcotic pain management solutions, erectile dysfunction treatments, and metabolic therapies. With a negative P/E ratio of -0.01 and a negative profit margin of -695.5%, the company's financial performance raises concerns. However, its low beta of 0.49 suggests lower volatility compared to the market. The company's growth potential hinges on expanding its market reach beyond the California workers' compensation system and securing additional preferred provider contracts. The gross margin of 29.4% indicates potential for profitability if operational efficiencies are improved. The absence of a dividend reflects the company's current focus on reinvesting earnings for growth. Future success depends on effective marketing, strategic partnerships, and successful product development.
Based on FMP financials and quantitative analysis
PXYN Key Highlights
Market capitalization of $0.00B indicates a micro-cap company with limited market presence.
- P/E ratio of -0.01 reflects negative earnings, suggesting the company is currently not profitable.
- Profit margin of -695.5% indicates significant losses relative to revenue.
- Gross margin of 29.4% shows the percentage of revenue exceeding the cost of goods sold.
- Beta of 0.49 suggests the stock is less volatile than the overall market.
Who Are PXYN's Competitors?
PXYN is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| MEDS TRxADE HEALTH, Inc. | $3.68 | -9.36% | $9.65M | — |
| MSLE Satellos Bioscience Inc. Common Stock | $8.50 | -0.12% | $11.0M | — |
| NEUP Neuphoria Therapeutics Inc. | $3.47 | -1.14% | $18.8M | — |
| AIXC AIxCrypto Holdings, Inc. | $1.01 | -39.16% | $20.4M | — |
| RNTX Rein Therapeutics, Inc. | $0.80 | -6.03% | $22.4M | — |
| KYNB Kyntra Bio, Inc. | $6.31 | -2.92% | $25.5M | — |
| YI 111, Inc. | $3.22 | -2.57% | $28.1M | — |
| PETS PetMed Express, Inc. | $1.36 | -0.73% | $29.1M | — |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PXYN's Key Strengths?
Focus on non-narcotic pain management solutions.
- Proprietary formulations and delivery systems.
- Established relationships with medical practitioners in California.
What Are PXYN's Weaknesses?
Limited market presence and brand awareness.
- High dependence on the California workers' compensation system.
- Negative profitability and financial performance.
What Are the Key Risks for PXYN?
Financial-distress signal — its Altman Z-Score of -2.83 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-20.2%) — the business is not currently generating profit on shareholder capital.
- Intense competition from larger pharmaceutical companies.
- Changes in regulations and reimbursement policies.
- Negative profitability and financial performance.
- Product liability claims related to medication side effects.
- Dependence on the California workers' compensation system.
What Are PXYN's Competitive Advantages?
- Focus on non-narcotic and non-habit forming medications.
- Specialization in transdermal and oral delivery systems.
- Established relationships with medical practitioners in California.
What Does PXYN Do?
Praxsyn Corporation, established in 2005 and headquartered in Las Vegas, Nevada, operates as a healthcare company focused on providing medical practitioners with medications and services for their patients. Originally named The PAWS Pet Company, Inc., the company transitioned to Praxsyn Corporation in March 2014, shifting its focus to human healthcare. Praxsyn formulates non-narcotic and non-habit forming medications using therapeutic and preventative agents. These medications are available in various forms, including transdermal creams, patches, and oral capsules, targeting conditions such as pain management, erectile dysfunction, and metabolic therapies. The company's primary market consists of patients covered under the California workers' compensation system, as well as those with preferred provider contracts. Praxsyn's commitment to non-narcotic alternatives positions it within a niche segment of the pharmaceutical industry, addressing the growing concern over opioid addiction and seeking safer treatment options.
What Products and Services Does PXYN Offer?
- Formulates non-narcotic and non-habit forming medications.
- Develops transdermal creams, patches, and oral capsules.
- Offers treatments for pain management.
- Provides medications for erectile dysfunction.
- Develops metabolic therapies.
- Serves patients covered under the California workers' compensation system.
- Works with preferred provider contracts.
How Does PXYN Make Money?
- Develops and manufactures non-narcotic medications.
- Markets and sells medications to medical practitioners.
- Generates revenue through direct sales and preferred provider contracts.
What Industry Does PXYN Operate In?
Praxsyn Corporation operates within the medical pharmaceutical sector, a segment experiencing growth driven by an aging population and increasing demand for innovative therapies. The market is characterized by intense competition from both large pharmaceutical companies and smaller, specialized firms. Praxsyn's focus on non-narcotic treatments aligns with the growing trend towards alternative pain management solutions, driven by concerns over opioid addiction. The company's success depends on its ability to differentiate itself through effective marketing, strategic partnerships, and successful product development.
Who Are PXYN's Key Customers?
- Medical practitioners
- Patients covered under the California workers' compensation system
- Patients with preferred provider contracts
Research confidence
Thin evidence — scoring coverage unknown. Treat this as a starting point, not a conclusion.
- ● Scoring coverage unknown
- ● No usable price
- ● No filing on record
- ● No analyst coverage
Financial Health
Praxsyn Corporation's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -2.83 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on equity for Praxsyn Corporation stands at -20.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -5.1%, showing how much profit it generates from its asset base. A current ratio of 1.28 indicates the company holds enough short-term assets to cover its near-term obligations.
Company Profile
Praxsyn Corporation operates in the Medical - Pharmaceuticals industry within the Healthcare sector. It is headquartered in Las Vegas, US. The company is led by CEO Sean Daly. PXYN has traded publicly since 2010.
PXYN Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
PXYN Latest News
No recent news available for PXYN.
PXYN Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for PXYN.
Price Targets
Wall Street price target analysis for PXYN.
PXYN MoonshotScore
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. No MoonshotScore is published for PXYN; grades run from A+ (80-100) to F (below 30).
Leadership: Sean Daly
CEO
Sean Daly serves as the CEO of Praxsyn Corporation, leading a team of 66 employees. As CEO, he is responsible for the overall strategic direction and operational performance of the company, guiding its efforts in developing and marketing non-narcotic medications and services to medical practitioners.
Track Record: Information regarding Sean Daly's specific achievements, strategic decisions, and company milestones under his leadership is not available. His tenure at Praxsyn Corporation is focused on navigating the competitive pharmaceutical landscape and driving growth through product innovation and market expansion.
PXYN OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Praxsyn Corporation may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited operating history, minimal assets, and may not be subject to regular audits. Investing in OTC Other stocks carries significant risks due to the lack of transparency and regulatory oversight compared to exchanges like the NYSE or NASDAQ. This tier is often populated by shell companies, bankrupt entities, or companies with questionable business practices.
- OTC Tier: OTC Other
- Limited regulatory oversight and disclosure requirements.
- Potential for price manipulation and fraud.
- Higher risk of delisting and illiquidity.
- Lack of readily available financial information.
- Increased volatility due to low trading volume.
- Verify the company's legal standing and registration.
- Obtain and review audited financial statements.
- Assess the company's business model and competitive landscape.
- Evaluate the management team's experience and track record.
- Determine the company's compliance with securities laws.
- Understand the company's capital structure and ownership.
- Assess the liquidity and trading volume of the stock.
- Company has been in operation since 2005.
- Focus on providing medications to medical practitioners.
- Formulates non-narcotic and non-habit forming medications.
What Investors Ask About Praxsyn Corporation (PXYN) — Healthcare
What do analysts say about PXYN stock?
Currently, there is no available analyst coverage or consensus on Praxsyn Corporation (PXYN) stock. The company's micro-cap status and OTC listing may limit its visibility to institutional investors and research firms.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
MoonshotScore is not published for this security.
Data provided for informational purposes only.
- Limited financial information available for Praxsyn Corporation.
- OTC market carries higher risks than listed exchanges.